Ginkgolic acid inhibits the growth of renal cell carcinoma cells via inactivation of the EGFR signaling pathway.
epidermal growth factor receptor
ginkgolic acid
network pharmacology
renal cell carcinoma
traditional Chinese medicine
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
18
06
2019
accepted:
09
01
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
ppublish
Résumé
Renal cell carcinoma (RCC) is one of the most common urological malignancies occurring in adult human kidneys worldwide. Recent research on antitumor drugs has focused on plant extracts, a class of compounds that play critical roles in cancer treatment. The present study aimed to investigate the potential antitumor effect of ginkgolic acid (GA) in RCC. Transwell invasion assay, cell counting kit-8 assay and flow cytometry were used to measure cell migration, cell viability and apoptosis, respectively. A network pharmacology approach was applied to identify pathway information, combining molecular docking techniques to screen for key target information. In the present study, GA inhibited the viability and proliferation of RCC cells (786-O and A498), both
Identifiants
pubmed: 32256780
doi: 10.3892/etm.2020.8570
pii: ETM-0-0-8570
pmc: PMC7086188
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2949-2956Informations de copyright
Copyright: © Zhu et al.
Références
Phytomedicine. 1999 Oct;6(4):281-3
pubmed: 10589448
BMC Bioinformatics. 2016 Jul 25;17 Suppl 7:269
pubmed: 27454228
Biochem Biophys Res Commun. 2011 Feb 11;405(2):153-6
pubmed: 21232526
Oncol Lett. 2017 Nov;14(5):5831-5838
pubmed: 29113214
Mol Inform. 2017 Oct;36(10):
pubmed: 28692140
Cell. 2005 Sep 23;122(6):957-68
pubmed: 16169070
Front Pharmacol. 2018 Aug 06;9:841
pubmed: 30127739
Onco Targets Ther. 2018 Sep 25;11:6209-6216
pubmed: 30288056
Mol Cancer. 2018 Feb 19;17(1):53
pubmed: 29455669
J Chromatogr A. 2001 Sep 28;930(1-2):109-17
pubmed: 11681568
Molecules. 2017 Jul 07;22(7):
pubmed: 28686181
Cell. 2017 Oct 19;171(3):683-695.e18
pubmed: 28988771
Methods Mol Biol. 2017;1652:3-35
pubmed: 28791631
Oncol Rep. 2012 Sep;28(3):999-1005
pubmed: 22736024
Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F145-F154
pubmed: 28381462
Tumour Biol. 2017 May;39(5):1010428317705337
pubmed: 28513300
IEEE Rev Biomed Eng. 2010;3:120-54
pubmed: 22275205
Oncotarget. 2017 May 23;8(21):35103-35115
pubmed: 28402272
J Nephrol. 2015 Dec;28(6):647-57
pubmed: 26341657
Med Sci Monit. 2012 Aug;18(8):BR293-298
pubmed: 22847190
Sci Rep. 2015 Aug 25;5:13470
pubmed: 26304749
Cancer. 2005 Oct 1;104(7):1362-71
pubmed: 16116599
Exp Cell Res. 2003 Mar 10;284(1):2-13
pubmed: 12648462
FEBS Open Bio. 2014 Nov 04;4:952-65
pubmed: 25426415
Sichuan Da Xue Xue Bao Yi Xue Ban. 2009 May;40(3):459-61
pubmed: 19627005
Nucleic Acids Res. 2002 Jan 1;30(1):303-5
pubmed: 11752321
J Cell Physiol. 2017 Feb;232(2):346-354
pubmed: 27177359
Mol Oncol. 2018 Jan;12(1):3-20
pubmed: 29124875
Oncol Rep. 2019 Jan;41(1):369-376
pubmed: 30320342
Chemotherapy. 2010;56(5):393-402
pubmed: 20948210
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Toxicology. 2002 Aug 15;177(2-3):167-77
pubmed: 12135620
Biochem Biophys Res Commun. 2018 Mar 25;498(1):246-253
pubmed: 29353042
Oncotarget. 2015 Aug 28;6(25):20993-1003
pubmed: 25895130
Science. 1967 Sep 15;157(3794):1270-3
pubmed: 5341600
Cancer. 2010 Jan 15;116(2):347-54
pubmed: 19921736
Chin J Integr Med. 2011 Sep;17(9):698-703
pubmed: 21910072
Oncol Lett. 2017 Apr;13(4):2053-2058
pubmed: 28454361
PLoS One. 2014 Aug 05;9(8):e102506
pubmed: 25093322
Cancer Sci. 2017 Aug;108(8):1620-1627
pubmed: 28612496